Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...

SIGN UP TO CONTINUEPrint Subscriber? Sign Up for Full Access!Please sign up for as low as 36 cents per day to continue ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Vaccine maker Moderna's (NASDAQ: MRNA) stock prices fell by over 16% on 13th January to close at £28.81 ($35.15) after the ...

U.S. stock futures are pointing higher ahead of wholesale inflation data, China mulls selling TikTok to Elon Musk, and ...

Moderna stock slid nearly 17% on Monday, after the US biotech firm slashed its 2025 sales forecast range by $1bn. An ...

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...